Decibel Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DBTX research report →
Price Chart
About the company
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1.
- CEO
- Laurence E. Reid
- IPO
- 2021
- Employees
- 68
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on DBTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $123.37M
- P/E
- -1.95
- PEG
- 0.39
- P/S
- 0.00
- P/B
- 1.50
- EV/EBITDA
- -1.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.38%
- ROIC
- -61.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-63,957,000
- Net Income
- $-63,005,000-21.6%
- EPS
- $-2.52-5.9%
- OCF Growth
- -31.9%
- FCF Growth
- -30.7%
- 52W High
- $5.40
- 52W Low
- $1.61
- 50D MA
- $4.29
- 200D MA
- $3.62
- Beta
- -0.40
- RSI (14)
- 52
- Avg Volume
- 214.74K
No earnings-call transcripts are available for DBTX yet.
- Free Float
- 53.3%
- Shares Outstanding
- 25.13M
- Float Shares
- 13.40M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 23 | Trask Anna | sell | 106,864 |
| Sep 25, 23 | Trask Anna | sell | 45,000 |
| Sep 25, 23 | Trask Anna | sell | 52,500 |
| Sep 25, 23 | Trask Anna | sell | 137,302 |
| Sep 25, 23 | Carson William H. | sell | 10,000 |
| Sep 25, 23 | Carson William H. | sell | 5,000 |
| Sep 25, 23 | Carson William H. | sell | 5,000 |
| Sep 25, 23 | Carson William H. | sell | 20,000 |
| Sep 25, 23 | Lee John Jui-Jen | sell | 147,144 |
| Sep 25, 23 | Lee John Jui-Jen | sell | 45,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DBTX coverage
Recent articles, reports, and earnings notes.
No research on DBTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DBTX report →Decibel Therapeutics' CVR Appears Around Fair Value
seekingalpha.com · Sep 15
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
businesswire.com · Sep 5
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
businesswire.com · Aug 12
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
globenewswire.com · Aug 11
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
investopedia.com · Aug 9
Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron
prnewswire.com · Aug 9
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
businesswire.com · Aug 9
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
investorplace.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.